Skip to main content
Menu Search & Directory

Cancer Clinical Trials

SLUCare specialists in hematology, oncology and cellular therapy are committed to leadership in clinical research programs. As the faculty of Saint Louis University School of Medicine, our staff regularly conducts clinical trials of new medicines and technologies. The following studies are now seeking participants.


Defining How Patient BMI Influences the Response to Immunotherapy for Cancer

Dr. Ryan Teague

A study to determine how immunotherapy influences BMI in patients with any cancer planned to receive Pembrolizumab, Atezolizumab, Ipilimumab, Nivolumab, or Durvalumab

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Alliance/ A051301 - Dr. Sagun Goyal

A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

ECOG-ACRIN/ EA4151 - Dr. Sagun Goyal

A randomized phase III trial of consolidation with autologous hematopoietic cell transplantation followed by maintenance rituximab vs. maintenance rituximab alone for patients with mantle cell lymphoma in minimal residual disease-negative first complete remission

A Study of Retreatment with Brentuximab Vedotin in Subjects with Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

SeattleGenetics/ SGN35-028 - Dr. Sagun Goyal

A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL)

Randomized, Open-Label, Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2/M20-178)

AbbVie/ M20-178 - Dr. Abishek Chilkulwar

Navitoclax is an investigational drug (not yet approved) being developed for the treatment of Myelofibrosis (MF). The study has 2 arms - A and B. In Arm A, participants will receive navitoclax in combination with ruxolitinib. In Arm B, participants will receive the best available therapy (BAT) for MF. Adult participants with a diagnosis of relapsed/refractory (R/R) MF will be enrolled.

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Merck/ LEAP-012: MK7902-012 - Dr. John Richart

A phase 3 multicenter, randomized, double-blinded, active-controlled, clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) with pembrolizumab (MK-3475) in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

SeattleGenetics / SGN35-031 - Dr. Nabeel Rajeh

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone.

Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Incyte/GRAVITAS-309 - Dr. Nabeel Rajeh

The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).

A five-year longitudinal observational study of the natural history and management of patients with hepatocellular carcinoma.

Target PharmaSolutions/TargetHCC - Dr. John Richart

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

Immunological Response to Infection, Vaccination, and Disease.

Dr. James Brien

A study to determine immune response to the SARS-CoV-2 vaccine in patients who have blood cancers who will be or have been treated with bone marrow transplant. 

Randomized, Open-Label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy.

AbbVie/M19-708 - Dr. Abhishek Chilulwar

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with AZA. Part 3 will be conducted in 2 phases - Dose Finding portion to determine RPTD of venetoclax in combination with CC-486 and Randomization portion to evaluate if venetoclax in combination with CC-486 as maintenance therapy improves relapse-free survival (RFS) compared to CC-486.

A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

POINT BioPharma/PBP-301 - Dr. Medhat Osman

The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer

AstraZenica/PACIFIC4 - Dr. Jeevin Shahi

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dociparstat sodium in combination with standard chemotherapy for the treatment of newly-diagnosed acute myeloid leukemia (DASH AML)

Chimerix/CMX-DS-003 - Dr. Nabeel Rajeh

Phase 3 study to evaluate the efficacy and safety of dociparstat sodium in adults with newly diagnosed untreated AML with adverse or intermediate genetic risk.